Effector Therapeutics Stock Cash Flow From Operations
| EFTRWDelisted Stock | USD 0 0.00 0.00% |
EFFECTOR Therapeutics fundamentals help investors to digest information that contributes to EFFECTOR Therapeutics' financial success or failures. It also enables traders to predict the movement of EFFECTOR Pink Sheet. The fundamental analysis module provides a way to measure EFFECTOR Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to EFFECTOR Therapeutics pink sheet.
EFFECTOR |
EFFECTOR Therapeutics Company Cash Flow From Operations Analysis
EFFECTOR Therapeutics' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current EFFECTOR Therapeutics Cash Flow From Operations | (29.55 M) |
Most of EFFECTOR Therapeutics' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, EFFECTOR Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
CompetitionIn accordance with the recently published financial statements, EFFECTOR Therapeutics has (29.55 Million) in Cash Flow From Operations. This is 105.6% lower than that of the Biotechnology sector and 147.26% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 103.04% higher than that of the company.
EFFECTOR Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses EFFECTOR Therapeutics' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of EFFECTOR Therapeutics could also be used in its relative valuation, which is a method of valuing EFFECTOR Therapeutics by comparing valuation metrics of similar companies.EFFECTOR Therapeutics is currently under evaluation in cash flow from operations category among its peers.
EFFECTOR Fundamentals
| Return On Equity | -9.47 | |||
| Return On Asset | -0.83 | |||
| Number Of Shares Shorted | 18.44 K | |||
| EBITDA | (33.73 M) | |||
| Net Income | (35.81 M) | |||
| Total Debt | 19.45 M | |||
| Book Value Per Share | 0.21 X | |||
| Cash Flow From Operations | (29.55 M) | |||
| Earnings Per Share | (0.91) X | |||
| Number Of Employees | 14 | |||
| Beta | 0.62 | |||
| Total Asset | 20.54 M | |||
| Retained Earnings | (179.38 M) | |||
| Working Capital | (5.96 M) | |||
| Net Asset | 20.54 M |
About EFFECTOR Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze EFFECTOR Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EFFECTOR Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of EFFECTOR Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in EFFECTOR Pink Sheet
If you are still planning to invest in EFFECTOR Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EFFECTOR Therapeutics' history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |